Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27th 2025

By Skylar Jeremias

Article

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26th 2025

By Skylar Jeremias

Article

Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients.

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25th 2025

By Rose McNulty

Article

New research confirms the romiplostim biosimilar GP40141 offers comparable efficacy and safety for treating immune thrombocytopenia, enhancing treatment accessibility.

The Top 5 Biosimilar Articles for the Week of August 18

August 22nd 2025

By Skylar Jeremias

Article

Here are the top 5 biosimilar articles for the week of August 18, 2025.

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22nd 2025

By Skylar Jeremias

Article

A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

August 19th 2025

By Skylar Jeremias

Article

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative access strategies for patients.

The Top 5 Biosimilar Articles for the Week of August 11

August 15th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 11, 2025.

Denosumab Biosimilar LY01011 Shows Equivalence to Reference Product for Bone Metastases

August 14th 2025

By Cameron Santoro

Article

Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable safety profiles, and a lack of unexpected adverse reactions.

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

August 13th 2025

By Skylar Jeremias

Article

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Japanese Study Provides Postapproval Insights Into Biosimilar Quality Attributes

August 12th 2025

By Skylar Jeremias

Article

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and public confidence in these therapies.